相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Oncology
Sophie M. Ernst et al.
Summary: Next-generation sequencing allows for the reclassification of smoking-associated NSCLC based on individual genomic tumor characteristics, which can help reduce lung cancer stigma.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Review
Oncology
Nicholas Bradley Larson et al.
Summary: Next-generation sequencing (NGS) technologies, widely used in cancer research, generate vast and diverse data that require sophisticated computational methods and bioinformatics expertise. This review provides background details of NGS technology and basic bioinformatics concepts for clinicians interested in cancer research applications, with a focus on DNA-based approaches. It introduces principles of library preparation, alignment, variant calling, variant annotations, and NGS applications for other molecular data types. The review also discusses the utility of NGS methods in NSCLC research and study design considerations for leveraging NGS technologies in clinical care.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Tetsuya Mitsudomi et al.
Summary: This study provides consensus recommendations for biomarker testing in Asian patients with non-small cell lung cancer. It highlights the importance of analyzing actionable genetic alterations in EGFR, ALK, ROS1, and others, including uncommon EGFR mutations. The role of liquid biopsy in assessing tumor biomarkers is also discussed.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Vivek Subbiah
Summary: Technological advances are transforming evidence generation in medicine, but the clinical trial landscape must adapt to keep pace. Wearable technologies, data science, and machine learning offer a glimpse into the future of evidence-based medicine. Despite advances, clinical translations in major areas of medicine are lagging. The COVID-19 pandemic exposed limitations but also spurred positive changes like new trial designs and a shift towards a patient-centric evidence-generation system.
Review
Pharmacology & Pharmacy
Clara Bourreau et al.
Summary: Although new targeted therapies have improved the treatment and prognosis of non-small cell lung cancer, they often fail due to primary or acquired resistances. Chemoresistance is a complex process involving various factors. Two approaches that could improve treatment response are developing predictive tools and understanding the influence of the tumor microenvironment. Personalized medicine requires identifying relevant experimental models and biomarkers to combat chemoresistance.
PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Pathology
Alberto Pisacane et al.
Summary: The aim of this study is to develop a simplified pathological workflow to exclude CUPs in patients with MUOs. A total of 64 MUOs were classified using standard histopathology, and clinical data, immunocytochemical markers, and molecular analysis results were recorded. The majority of MUOs were confirmed as CUP, while a small portion displayed clear carcinoma features. The findings support the use of a simplified histological approach to exclude CUP and early metastatic cancers.
Review
Oncology
Xinyu Wu et al.
Summary: Immune checkpoint inhibitors (ICIs), such as PD-1 and PD-L1 inhibitors, and CTLA-4 inhibitors, have shown significant improvement in the prognosis of early-stage NSCLC in multiple clinical trials. However, the target population for immunotherapy and the predictive biomarkers for neoadjuvant immunotherapy selection are still under discussion. Potential biomarkers being explored include PD-L1 expression, tumor mutation burden, circulating tumor DNA, tumor microenvironment components, and clinical factors.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Niamh Coleman et al.
Summary: Antibody-drug conjugates (ADCs) are a growing class of oncology drugs that combine cytotoxic chemotherapy with targeted therapy to deliver potent agents to cancer cells. In lung cancer treatment, ADCs have emerged as potential options, with FDA-approved and breakthrough therapy designated ADCs available. Early-phase trials are also exploring novel ADCs for advanced lung cancer. This review discusses the structure, mechanism of action, recent progress, toxicity profiles, and strategies to enhance potency and overcome resistance of ADCs in lung cancer, as well as novel ADC strategies using non-cytotoxic payloads.
NPJ PRECISION ONCOLOGY
(2023)
Article
Medical Laboratory Technology
Fernando Schmitt et al.
Summary: The understanding of molecular mechanisms in lung cancer and the discovery of targetable genomic alterations have significantly changed the pathological approach to lung cancer, particularly non-small cell lung cancer (NSCLC). Pathologists have been at the forefront of lung cancer management due to this unstoppable knowledge. In the field of cytopathology, where maximizing output with minimal input is a daily challenge, there has been a paradigm shift in the care and handling of diagnostic samples. This shift emphasizes the utilization of cytologic samples and small biopsies for both diagnostic and ancillary testing purposes.
DIAGNOSTIC CYTOPATHOLOGY
(2023)
Review
Oncology
Matthieu Roulleaux Dugage et al.
Summary: Immunotherapy with immune-checkpoint inhibitors (ICIs) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). It has shown promising results in early NSCLC, especially with neoadjuvant multimodality approaches. However, biomarkers for predicting response to ICIs in early-stage NSCLC are lacking. PD-L1 expression and tumor mutational burden seem to correlate with better response rates and survival. Other promising approaches include blood-based ratios, microbiota, and baseline intratumoral TCR clonality. Circulating tumor DNA could help in selecting best candidates for adjuvant ICIs and monitoring tumor response.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Antonio Passaro et al.
Summary: Antibody-drug conjugates (ADCs) combine the cytotoxic effect of payload with the specific ability of monoclonal antibody targeting cancer cells. ADCs targeting antigens expressed in lung cancer cells show promising results, particularly in non-small-cell lung cancer. Multiple ADCs are currently under evaluation, either alone or in combination with other molecules, to develop optimal treatment strategies for lung cancer patients. Understanding biomarkers related to resistance and response to the payload is also crucial in improving ADC therapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Lissete Sanchez-Magraner et al.
Summary: Immunomodulatory ligand-receptor interactions play a crucial role in cancer immunoevasion. A study on non-small cell lung carcinoma patients revealed the heterogeneity of PD-1/PD-L1 immune checkpoint engagement and its correlation with treatment response. The functional readout of PD-1/PD-L1 interaction can significantly improve patient stratification for immunotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Charles M. M. Rudin et al.
Summary: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine carcinoma with limited treatment options. DLL3, a Notch inhibitory ligand, is overexpressed on SCLC cells, making it an attractive therapeutic target. This article discusses the clinical experience with a DLL3-targeting antibody-drug conjugate called Rova-T, as well as other DLL3-targeting agents currently in development, including T-cell engager molecules and CAR T-cell therapy. The challenges and opportunities for DLL3-targeting therapies, such as using DLL3 as a biomarker and exploring combinatorial approaches, are also discussed.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Letter
Oncology
Kei Kunimasa
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Hyun-Ae Jung et al.
Summary: This study evaluated the feasibility and efficacy of longitudinal monitoring of circulating tumor DNA (ctDNA) as a valuable biomarker for early detection of minimal residual disease (MRD) and identifies high-risk group for recurrence in resected stages I to IIIA EGFR-M+ NSCLC. The results showed that baseline ctDNA positivity was associated with poor disease-free survival (DFS) and ctDNA monitoring detected minimal residual disease before radiological recurrence.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Letter
Oncology
Fei Zhou et al.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Joao V. Alessi et al.
Summary: The efficacy of chemoimmunotherapy (CIT) in advanced NSCLC is associated with factors such as performance status, neutrophil-to-lymphocyte ratio, PD-L1 expression, and tumor mutational burden.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Review
Oncology
Guilherme Harada et al.
Summary: Lung cancers with rare alterations can be detected in a significant number of patients and are amenable to specific therapies. This review provides an overview of the epidemiology, diagnosis, prognosis, and treatment of lung cancers with rare alterations, emphasizing the importance of expedited drug approval pathways and cooperation between stakeholders.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Masahiro Tsuboi et al.
Summary: Among patients with resected, EGFR-mutated, stage IB to IIIA NSCLC, adjuvant osimertinib therapy resulted in significantly longer overall survival compared to placebo in the ADAURA trial. These findings demonstrate that adjuvant osimertinib provides a survival benefit for patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Pathology
Jakob Einhaus et al.
Summary: High-multiplex tissue imaging (HMTI) methods enable in-depth, spatial single-cell analysis and have been used in tumor biology, infectious diseases, and autoimmune conditions to map complex tissues and gain valuable information. Integrating HMTI technologies into clinical workflows can improve patient outcomes through personalized treatments tailored to the specific heterogeneous pathological fingerprint of diseases.
Article
Oncology
Marcelo Negrao et al.
Summary: In this study, co-occurring genomic alterations in KEAP1, SMARCA4, and CDKN2A were identified as independent determinants of poor clinical outcomes with KRASG12Ci monotherapy in advanced NSCLC. A framework for patient stratification and treatment personalization based on the comutational status of individual tumors is proposed. These findings provide important insights for rational selection and appropriate tailoring of emerging combination therapies for KRASG12C-mutant NSCLC.
Article
Chemistry, Multidisciplinary
Ming-You Shie et al.
Summary: Despite ongoing research, lung cancer remains a significant health problem. A patient-specific ex vivo spheroid model has been developed to accurately investigate the cause, metastasis, and treatment strategies for lung cancer. This model, consisting of patient-derived tumor spheroids, endothelial cells, and lung decellularized extracellular matrix, mimics the behavior of native tumors and can be used for personalized cancer therapy and improved clinical care.
Article
Oncology
L. E. Hendriks et al.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
L. E. Hendriks et al.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
A. Bayle et al.
Summary: This study demonstrates that comprehensive molecular profiling of ctDNA is a promising approach for tailoring therapy in patients with advanced solid tumors, resulting in positive clinical outcomes.
ANNALS OF ONCOLOGY
(2023)
Article
Medical Laboratory Technology
Denis Horgan et al.
Summary: The background of this debate is the EU's decision to tighten controls on the devices and diagnostics sector, which led to the adoption of a regulation with a schedule for implementation. The recent deferral of implementation deadlines has exposed ongoing challenges in terms of awareness and implementation of the regulation across Europe. There is limited awareness of the In Vitro Diagnostic Regulation (IVDR) and the different national systems involved, which poses risks for patient and consumer access to in vitro diagnostics (IVDs). The proposed solutions so far remain more aspirational than practical.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Oncology
Edurne Arriola et al.
JCO Precision Oncology
(2023)
Article
Simon Kreutzfeldt et al.
JCO Clinical Cancer Informatics
(2023)
Article
Medicine, General & Internal
Denis Horgan et al.
Summary: Growing awareness of the genetic basis of disease is changing the landscape of personalized medicine and diseases diagnostics. The success of this transformation depends on a unified approach to regulation within the European Union. The current proposed European Health Data Space raises concerns regarding its compatibility with data generation constraints, potential overlaps with existing legislation, and lack of funding clarity.
Article
Samuel Rosner et al.
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
(2023)
Review
Oncology
Federica Pezzuto et al.
Summary: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Significant progress has been made in the treatment of non-squamous NSCLC through the identification of oncogenic drivers and the development of targeted therapies. However, resistance to targeted therapy and the heterogeneity of oncogene-driven clusters pose challenges. This review focuses on the prognostic and predictive significance of oncogene-driven co-mutations, particularly in relation to EGFR and TP53.
Article
Rocco Trisolini et al.
JTO Clinical and Research Reports
(2023)
Article
Jay M. Lee et al.
JTO Clinical and Research Reports
(2023)
Article
Raymond Diep et al.
JTO Clinical and Research Reports
(2023)
Article
Oncology
A. Bayle et al.
Summary: This study provides a comprehensive overview of the availability and accessibility of biomolecular technologies to cancer patients in Europe. The study finds that advanced biomolecular technologies are often inaccessible in clinical practice and limited to clinical trials or basic research. The main barriers to access are the reimbursement of the test and the availability of a suitable medicine.
ANNALS OF ONCOLOGY
(2023)
Review
Oncology
Edwin Roger Parra et al.
Summary: Over the past decade, there has been a revolution in cancer treatment with the shift towards targeted molecular therapies and immune-based therapies, particularly immune-checkpoint inhibitors (ICIs). However, not all patients with advanced non-small cell lung cancer (aNSCLC) benefit equally from immunotherapy, and there is a need for additional predictive markers for ICIs efficacy. Multiplex immunostaining, which evaluates multiple molecules in the tumor at the same time, shows promise in optimizing patient selection for ICIs. This review aims to explore the role of multiplex immunostaining in immuno-thoracic oncology and its current advantages and limitations in clinical practice.
BRITISH JOURNAL OF CANCER
(2023)
Review
Oncology
Soo-Ryum Yang et al.
Summary: Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the clinical management of patients with advanced NSCLC. The development of targeted therapies for specific genomic alterations and the emergence of immune-checkpoint therapy have revolutionized treatment options for these patients. However, identification of predictive biomarkers for immune-checkpoint inhibition remains a challenging area of research. The use of biomarkers and alternative genotyping methods has become increasingly integrated into clinical practice.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Paolo Tarantino et al.
Summary: Recent years have seen a shift in cancer treatment towards therapies tailored to specific molecular aberrations and immunologic markers, rather than solely relying on histology. Several histology-agnostic therapies are now adopted in clinical practice for treating patients, and novel antibody-drug conjugates (ADCs) have shown promise in treating solid tumors. The multihistological expansion of ADCs poses both challenges and opportunities for cancer treatment.
CA-A CANCER JOURNAL FOR CLINICIANS
(2022)
Review
Oncology
Daniel Kazdal et al.
Summary: Targeted therapy is preferred over chemotherapy and immunotherapy for actionable gene fusions in late-stage non-small cell lung carcinoma (NSCLC) due to its superior efficacy and tolerability. Testing for ALK, ROS1, NTRK, and RET gene fusions is now mandatory for all newly diagnosed advanced non-squamous NSCLC patients. RNA next-generation sequencing (NGS) or combined DNA/RNA NGS is the preferred method for detecting gene fusions. Recent advancements have led to the discovery of new gene fusions, necessitating the development of comprehensive detection methods and promising therapies.
GENES CHROMOSOMES & CANCER
(2022)
Review
Oncology
Aaron C. Tan et al.
Summary: The therapeutic landscape of non-small-cell lung cancer is undergoing significant changes with the shift from histology-based classification to molecularly defined subsets. Targeted therapies for specific driver mutations such as EGFR, ALK, and ROS1 have shown promising results, and there is a growing list of approved therapies for other mutations. The importance of diagnostic molecular testing, optimal sequencing of therapies, application of targeted therapies in early-stage disease, and the impact of genomic mutations on targeted therapy efficacy are important areas of research.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Aakash Desai et al.
Summary: Antibody-drug conjugates (ADCs) are showing promise in the treatment of lung cancer, with several ADCs currently in clinical trials for NSCLC and SCLC. These ADCs target different molecules and novel methods are being developed to improve their safety and efficacy.
Review
Pathology
Vipul Baxi et al.
Summary: Recent technological advancements have enabled the development of digital pathology and AI-based solutions for quantitative pathologic assessments, revolutionizing disease diagnosis and drug development. These innovations provide valuable opportunities in immuno-oncology for deciphering complex pathophysiology and discovering novel biomarkers, while also supporting practitioners in selecting the most appropriate treatment based on patient profiles. The integration of AI-powered analysis tools enhances the traditional role of pathologists in delivering accurate diagnoses and assessing biomarkers, with potential applications in translational medicine and clinical settings.
Review
Oncology
Maryland Rosenfeld Franklin et al.
Summary: The field of immuno-oncology has seen significant changes, with a wide range of potential therapies and combinations being evaluated in clinical trials. Successful development of these therapies requires the use of appropriate tools and technologies, such as preclinical models, biomarkers, and efficient clinical trial designs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
D. Gale et al.
Summary: Detection of ctDNA using sensitive patient-specific assays after initial treatment has the potential to identify early-stage NSCLC patients who may benefit from further therapeutic intervention.
ANNALS OF ONCOLOGY
(2022)
Review
Oncology
Oriol Pich et al.
Summary: The translational challenges in the field of precision oncology are partly due to the complexity and diversity of cancer. Advances in genomics have enabled large-scale sequencing efforts and discoveries, impacting our understanding of cancer initiation, prevention, treatment, and other concepts. Key areas for improving cancer outcomes are discussed, along with the practical challenges of adopting molecular profiling in clinical settings and the need for robust translational infrastructure.
Review
Biochemistry & Molecular Biology
Fiorella Calabrese et al.
Summary: Patients with non-small cell lung cancer, especially adenocarcinomas, often have specific genetic mutations that can be targeted for therapy. While targeted treatments have improved patient outcomes, some patients may develop resistance to treatment. This review discusses the transformation of lung cancer into different histotypes and molecular mechanisms of resistance, providing a comprehensive overview of the topic.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
David S. Ettinger et al.
Summary: This passage introduces the recommended management for non-small cell lung cancer (NSCLC) in the NCCN Clinical Practice Guidelines, with a focus on targeted therapies for patients with metastatic NSCLC and actionable mutations.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Oncology
Andrew G. Nicholson et al.
Summary: The 2021 WHO Classification of Thoracic Tumours focuses on the application of genetics and molecular pathology, providing specific classifications and diagnostic criteria for various tumors, while emphasizing new tumor features and concepts.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Marius Ilie et al.
Summary: This study optimized two automated four-plex immunohistochemistry (mIHC) assays and evaluated the repeatability and concordance of cell density assessment. After optimization, the mIHC assay showed sensitive and repeatable assessment of eight diagnostic and predictive biomarkers for non-small cell lung cancer (NSCLC), providing a reliable method for clinical decision-making.
Review
Oncology
Richard Rosenquist et al.
Summary: Precision diagnostics is an important aspect of precision medicine, and whole-genome sequencing can be used to predict and respond to cancer treatment. National initiatives aim to introduce clinical whole-genome sequencing as a rational and effective diagnostic tool, but there is a lack of systematic evaluation of the clinical utility of whole-genome sequencing.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Xiaomeng Yin et al.
Summary: This article reviews the advancements in transformed small cell lung cancer, including clinical and pathological characteristics, and potential effective treatments after SCLC transformation, aiming to provide a better understanding of transformed SCLC and support for clinical use.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Immunology
Pavlina Spiliopoulou et al.
Summary: The cancer research community is searching for more biomarkers of response and resistance to immune checkpoint treatment, and analyzing the loss of the 9p21.3 locus may provide additional knowledge about immune evasion in cancer.
TRENDS IN IMMUNOLOGY
(2022)
Article
Oncology
Marius Ilie et al.
Summary: Due to the increasing complexity of genomic alterations in non-squamous non-small cell lung carcinoma (NS-NSCLC), it is challenging to evaluate biomarkers using sequential analyses. This study reports the development of an optimal workflow for genomic alteration assessment in routine clinical practice using ultra-fast next generation sequencing. The results demonstrate high concordance with gold standard methods and a quick turnaround time, even with a small amount of nucleic acids.
Review
Oncology
Christophe Bontoux et al.
Summary: RAS mutation is common in human cancers, with KRAS being the most frequently mutated gene. Recent developments in small molecule therapies targeting KRAS G12C mutations in non-small cell lung carcinomas (NSCLC) show promise, although co-mutations with STK11 or KEAP1 may lead to primary resistance to immune checkpoint inhibitors. Evaluating KRAS status is essential for optimal treatment strategies in advanced-stage NS-NSCLC.
Review
Oncology
Joanna Moes-Sosnowska et al.
Summary: Fibroblast growth factor receptor inhibitors are a potential therapeutic option for Sq-NSCLC, but the predictive potential of FGFR aberrations as biomarkers is unclear. FGFR mRNA overexpression, mutations, and fusions show promise, but further research is needed due to limited clinical data.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
E. Heitzer et al.
Summary: This paper reviews the challenges and current applications of ctDNA mutation testing in metastatic non-small cell lung cancer (NSCLC). The study finds that ctDNA mutation testing has potential value in complementing tissue biopsy, identifying resistance mechanisms, and assisting in therapy selection. It also provides insights into potential targets that may have been missed on tissue biopsy.
Article
Oncology
J. Pascual et al.
Summary: Circulating tumour DNA (ctDNA) assays conducted on plasma are proving to be valuable tools for identifying actionable mutations in patients with advanced cancer and for detecting molecular residual disease or relapse in early-stage cancer. However, tissue-based testing is still preferred due to the limitations of ctDNA assays.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Navneet Singh et al.
Summary: This study aims to provide updated evidence-based recommendations for systemic therapy in patients with stage IV non-small-cell lung cancer (NSCLC) with driver alterations. The recommendations were based on a systematic review of randomized control trials from 2020 to 2021. Different drugs are recommended for patients with different gene alterations.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Pathology
Denise Zou et al.
Summary: The study evaluated the diagnostic value and cost-effectiveness of NGS-based testing compared to various combinations of SGTs for first-line treatment selection in advanced/metastatic non-squamous non-small-cell lung cancer patients. The results showed that NGS testing offers a more comprehensive detection of actionable biomarkers and can increase the proportion of patients receiving biomarker-driven therapies.
JOURNAL OF MOLECULAR DIAGNOSTICS
(2022)
Article
Oncology
Xiaomeng Yin et al.
Summary: Lung cancer is the leading cause of malignancy-related deaths, with most patients being diagnosed at an advanced stage. Immunotherapy and targeted therapy have made significant progress in treating lung cancer, but their efficacy is inconsistent. Existing biomarkers for predicting treatment outcomes are unsatisfactory, necessitating the need for novel biomarkers. Artificial intelligence (AI) offers potential solutions by identifying features beyond human capability and performing repetitive tasks. By combining AI with various data sources, the integrated model shows promise in predicting treatment outcomes, thereby improving precision medicine for lung cancer patients.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Pathology
Frederique Penault-Llorca et al.
Summary: For patients with advanced non-small cell lung cancer, selecting appropriate tissue biopsy techniques is crucial. It is important to choose techniques that provide the greatest quantity and quality of tissue, and manage the processing according to biomarker testing requirements. Additionally, utilizing cytological material can provide essential data for molecular diagnoses.
Review
Pathology
Frederique Penault-Llorca et al.
Summary: This article summarizes evidence-based recommendations for analytical steps of biomarker testing in NSCLC, including reporting and quality assessment. Simultaneous testing of multiple actionable oncogenic drivers is imperative, and molecular tumor boards are recommended for interpreting complex genetic information and determining optimal treatment.
Article
Medical Laboratory Technology
Qiong Gan et al.
CLINICS IN LABORATORY MEDICINE
(2022)
Article
Oncology
Umberto Malapelle et al.
Summary: Liquid biopsy has brought about a revolutionary approach in managing cancer patients, especially when solid tissue biopsies are insufficient. It not only predicts cancer markers but also facilitates comprehensive tumor genotyping, identification of emergent resistance mechanisms, monitoring of minimal residual disease, early cancer detection, and cancer interception.
Review
Oncology
Bai Ling et al.
Summary: Proteomics is an emerging technology that can be used for the diagnosis, treatment, and prognosis of lung cancer by comparing the protein content between normal and tumor tissues, as well as for the exploration of disease biomarkers and therapeutic targets.
FRONTIERS IN ONCOLOGY
(2022)
Review
Health Care Sciences & Services
Nina Pujol et al.
Summary: Molecular diagnosis of lung cancer is a constantly evolving field that requires repeated testing to establish accurate molecular diagnosis and track disease evolution. The emergence of next-generation sequencing (NGS) has greatly facilitated molecular profiling in lung cancer.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Health Care Sciences & Services
Christophe Bontoux et al.
Summary: Despite the recent increase in the number of types of treatments, non-small-cell lung cancer (NSCLC) remains the major cause of death from cancer worldwide. There is an urgent need to develop new therapeutic strategies. Recent data from phase II trials have shed light on promising specific therapies for HER2-mutant NSCLC.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Véronique Hofman et al.
JTO Clinical and Research Reports
(2022)
Article
Oncology
Edwin Cuppen et al.
Summary: The combination of whole-genome and transcriptome sequencing (WGTS) is a comprehensive precision diagnostic test that is expected to transform diagnosis and treatment for cancer patients. However, there are barriers to the implementation and widespread adoption of this test, including considerations of utility in different cancer types, cost-effectiveness and affordability.
JCO PRECISION ONCOLOGY
(2022)
Editorial Material
Oncology
Anja Irmisch et al.
Summary: The Tumor Profiler Study combines a prospective diagnostic approach with an exploratory strategy to assess the relevance of in-depth tumor profiling in supporting clinical decision-making and improving the biological understanding of the disease.
Article
Oncology
Iris Kamer et al.
Summary: A lack of robust, accessible experimental models is a major obstacle in advancing cancer immunotherapy. This study aimed to develop an ex-vivo organ culture (EVOC) model for non-small cell lung cancer (NSCLC) immunotherapy, which reflected original tissue features and showed promising correlations with immune checkpoint inhibitor response. The study provides valuable insights into biomarkers for ICI-induced response in early stage NSCLC.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Oncology
Christian Rolfo et al.
Summary: Although precision medicine has had mixed impact on clinical management of patients with advanced-stage cancer overall, the advances have been dramatic for NSCLC, specifically lung adenocarcinoma, due to genomic complexity and increasing number of druggable oncogene drivers. Liquid biopsy serves as a practical alternative source for investigating tumor-derived somatic alterations, offering a minimally invasive approach for selecting targeted therapies. The most extensively studied methodology is plasma circulating tumor DNA, which has wide adoption as an alternative to tissue tumor genotyping, particularly in solid tumors like NSCLC.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Nasser H. Hanna et al.
Summary: The updated guidelines provide evidence-based recommendations for systemic therapy in stage IV NSCLC patients with driver alterations, based on systematic reviews of randomized controlled trials and meeting abstracts. These recommendations emphasize the importance of testing for targetable mutations before initiating therapy, and highlight the use of targeted therapies for specific alterations like ROS-1 fusions and BRAF V600e mutations.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Medicine, General & Internal
Baharia Mograbi et al.
Summary: This review discusses the utilization of immunotherapy in the first-line treatment of NSCLC, focusing on the association between mutations in STK11/LKB1 and the lack of response to immunotherapy. It also highlights the potential directions and key points for future research in this area.
Review
Medicine, General & Internal
Valentina Angerilli et al.
Summary: The current practice of pathology is influenced by the increasing complexity of modern medicine, especially precision oncology, as well as major technological advancements. In the era of next-generation technologies, pathologists are responsible for integrating and interpreting morphologic and molecular information, delivering critical answers to diagnostic, prognostic, and predictive queries, and playing a prominent role in molecular tumor boards.
Article
Oncology
Benjamin H. Kann et al.
Summary: This article discusses the challenges faced in clinical oncology, proposes a pathway for narrow-task AI applications in clinical cancer care, and emphasizes the importance of clinical validity, utility, and usability.
Review
Oncology
Pasquale Pisapia et al.
Summary: Lung cancer is the leading cause of cancer death worldwide, with liquid biopsy technology showing promising applications in NSCLC patients. Molecular profiling of liquid biopsy specimens using next generation sequencing technologies is rapidly evolving.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Apar Kishor Ganti et al.
Summary: In this study, the latest US data show a decreasing overall incidence of non-small cell lung cancer (NSCLC) from 2010 to 2017, while the incidence of early stage I disease has risen. NSCLC prevalence has increased, and the estimated 5-year survival rate was found to be 26.4%; a significant proportion of patients aged 65 years or older with stage IV disease were not treated.
Review
Oncology
Paul Hofman
Summary: Liquid biopsy (LB) has become the only option to detect molecular targets for first-line treatment in treatment-naive NSCLC patients. Despite not being commonly used in diagnosis currently, Next-Generation Sequencing (NGS) shows the most promise for assessing genetic abnormalities.
Article
Oncology
Daniel Kazdal et al.
Summary: The research investigates the potential suitability of digital pathology tools in estimating tumor cell content accurately, showing higher agreement between semi-automatic tools compared to conventional methods and highlighting the benefits of computer-assisted analysis in improving accuracy and reliability in molecular diagnostic workflows.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Immunology
Xiaohua Li et al.
Summary: High-mutated NOTCH signaling may serve as an independent predictor of prognosis for NSCLC patients receiving ICIs, leading to significantly improved progression-free survival and prolonged overall survival. It is also associated with an inflammatory immune microenvironment, inflammatory expression profile, and enhanced immunogenicity. Further prospective clinical studies and molecular mechanism explorations are necessary for validation.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Cell Biology
Paul Hofman
Summary: The emergence of novel neoadjuvant and/or adjuvant therapies for early stage NSCLC requires the evaluation of predictive biomarkers, with treatment choices currently depending on immunohistochemistry results and EGFR/ALK status. This has led to challenges for clinical and molecular pathology laboratories to adapt to the new landscape.
Review
Cell Biology
Subasri Armon et al.
Summary: In France in 2020, lung cancers, particularly adenocarcinomas, ranked third in cancer incidence, with a focus on the tumor suppressor gene SMARCA4, impacting younger male smokers. These SMARCA4-deficient adenocarcinomas display aggressive behavior, leading to poor clinical outcomes despite early detection.
Review
Oncology
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY
(2020)
Review
Pathology
Xavier Matias-Guiu et al.
Article
Oncology
Kai Zhang et al.
CLINICAL CANCER RESEARCH
(2020)
Review
Oncology
Erik Thunnissen et al.
TRANSLATIONAL LUNG CANCER RESEARCH
(2020)
Review
Oncology
F. Mosele et al.
ANNALS OF ONCOLOGY
(2020)
Review
Respiratory System
Paul Hofman
JOURNAL OF THORACIC DISEASE
(2019)
Review
Oncology
Paul Hofman et al.
Review
Pathology
Paul Hofman et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
(2019)
Article
Oncology
Kaustav Bera et al.
NATURE REVIEWS CLINICAL ONCOLOGY
(2019)
Review
Medicine, General & Internal
Ivraym Barsoum et al.
Article
Medical Laboratory Technology
Neal I. Lindeman et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2018)
Review
Oncology
Veronique Hofman et al.
Article
Oncology
Kevin Washetine et al.
Review
Oncology
Simon Heeke et al.
TRANSLATIONAL LUNG CANCER RESEARCH
(2018)
Article
Oncology
Pamela Villalobos et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2017)
Review
Pathology
Elodie Long-Mira et al.
Article
Medical Laboratory Technology
Junya Fujimoto et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY
(2014)
Review
Biochemistry & Molecular Biology
M. Ilie et al.
CURRENT MEDICINAL CHEMISTRY
(2012)
